Doctor Adam Ioannou
UCL, Greater London (United Kingdom of Great Britain & Northern Ireland)
Prognostic importance of the 6-minute walk test in transthyretin cardiac amyloidosis
Event: Heart Failure 2024
Topic: Epidemiology, Prognosis, Outcome
Session: Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment
Tracking treatment response in cardiac AL amyloidosis with native-T1 mapping
Event: Heart Failure 2023
Topic: Imaging
Session: Cardiac amyloidosis from epidemiology to treatment
Tracking multi-organ treatment response in systemic AL amyloidosis with cardiac magnetic resonance derived extracellular volume mapping
Event: EACVI 2023
Topic: Myocardial Disease
Session: Young Investigators Award Clinical Cardiology
Tracking treatment response in cardiac AL amyloidosis with native-T1 mapping
Event: EACVI 2023
Topic: Myocardial Disease
Session: Dechiphering the phenotypes and dynamics of cardiomyopathies under the light of multi-modality imaging
Automated analysis of echocardiograms at diagnosis is able to predict prognosis in ATTR cardiomyopathy
Event: EACVI 2023
Topic: Myocardial Disease
Session: Cardiac Amyloidosis 1
Myocardial ischaemia in cardiac amyloidosis: a change of perspective
Event: ESC Congress 2022
Topic: Infiltrative Myocardial Disease
Session: A focus on cardiac amyloidosis
Multi-imaging characterisation of cardiac phenotype in different types of amyloidosis
Event: ESC Congress 2022
Topic: Infiltrative Myocardial Disease
Session: Cardiac amyloidosis
Changes in referral pathway and phenotypic status of patients diagnosed with ATTR cardiac amyloidosis during the past 20 years
Event: ESC Congress 2022
Topic: Infiltrative Myocardial Disease
Session: Cardiac amyloidosis: steps ahead
